Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
This collaboration turns kitting into a strategic advantage for sponsors and sites
Diversifying its portfolio to include late-phase antiviral agent
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Subscribe To Our Newsletter & Stay Updated